At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 129 enrolled
Drug / intervention
Sitagliptin +1 moredrug
Likely dose
Sitagliptin 25 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized Double-Blind Study to Evaluate the Efficacy and Safety of Sitagliptin Versus Glipizide in Participants With Type 2 Diabetes Mellitus and End-Stage Renal Disease Who Are on Dialysis and Who Have Inadequate Glycemic Control
In Brief
A Phase 3 clinical trial evaluating Sitagliptin and Glipizide for Diabetes Mellitus, Type 2 and End-Stage Kidney Disease. Completed, enrolled 129 participants.
Detailed Summary
The purpose of the study is to compare sitagliptin and glipizide in lowering blood sugar in participants with type-2 diabetes mellitus (T2DM) and end-stage renal disease on dialysis who do not have adequate glycemic control.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 2007
Enrollment StartOct 2007
Primary CompletionMar 2011
TodayJul 2026
First PostedJul 31, 2007
Enrollment StartOct 19, 2007
Primary CompletionMar 14, 2011
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 18.9 years ago
Interventions
Sitagliptindrug
25 mg (one 25-mg tablet) once daily
Glipizidedrug
2.5 mg (1/2 of a 5-mg tablet) once daily, up to 10 mg twice daily (four 5-mg tablets), for a maximum of 20 mg